No Significant Differences in Blood Loss or Clinical Outcomes with IA-TXA in ACL Reconstruction
Orthop J Sports Med. 2020 Jul; 8(7): 2325967120933135.Sixty patients scheduled for an anterior cruciate ligament (ACL) reconstruction for the treatment of an ACL tear were randomized to receive an intra-operative intra-articular injection of tranexamic acid (TXA) or no treatment. The primary outcome of interest was blood loss, calculated using hemoglobin levels. Secondary outcomes of interest included pain on a Visual Analog Scale (VAS), patellar circumference, range of motion and hemoglobin levels. No significant differences in all outcomes, at all time-points were observed between the TXA and control groups.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
